A Reliable Research Partner in Life Science and Medicine

Recombinant Human VEGFR-2/KDR protein (His tag)

Catalog No. PKSH033473

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description

Synonyms Vascular endothelial growth factor receptor 2, KDR, VEGFR-2, Fetal liver kinase 1,

FLK-1, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1,

CD309, Flk-1, FLK1, VEGFR, VEGFR2

Species Human

Expression Host HEK293 Cells
Sequence Met1-Glu764
Accession P35968
Calculated Molecular Weight 84.3 kDa
Observed molecular weight 90 kDa
Tag C-His

Bioactivity Testing in progress

Properties

Purity > 95 % as determined by reducing SDS-PAGE.

Endotoxin Please contact us for more information.

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to

-80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots

of reconstituted samples are stable at < -20°C for 3 months.

Shipping This product is provided as lyophilized powder which is shipped with ice packs.

Formulation Lyophilized from sterile PBS, pH 7.4.


Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as

protectants before lyophilization.

Please refer to the specific buffer information in the printed manual.

Reconstitution Please refer to the printed manual for detailed information.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

For Research Use Only

Toll-free: 1-888-852-8623 Tel: 1-832-243-6086 Fax: 1-832-243-6017

Web: www.elabscience.com

Email: techsupport@elabscience.com

Elabscience Bionovation Inc.



A Reliable Research Partner in Life Science and Medicine

VEGFR2, also called as KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as a major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling is critical to endothelial cell survival, maintenance of the vasculature and alveolar structure and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.

For Research Use Only

Toll-free: 1-888-852-8623 Tel: 1-832-243-6086 Fax: 1-832-243-6017 Email: techsupport@elabscience.com

Web: www.elabscience.com